Crosetti Erika, Borello Andrea, Bertolin Andy, Santos Izabela Costa, Fantini Marco, Arrigoni Giulia, Bertotto Ilaria, Sprio Andrea Elio, Dias Fernando Luiz, Rizzotto Giuseppe, Succo Giovanni
Otorhinolaryngology Unit, San Giovanni Bosco Hospital, 10154 Torino, Italy.
Otorhinolaryngology Unit, Michele and Pietro Ferrero Hospital, 12060 Verduno, Italy.
Curr Oncol. 2024 Dec 27;32(1):12. doi: 10.3390/curroncol32010012.
Early-stage laryngeal cancer (T1-T2) is commonly treated with organ-preserving techniques such as transoral laser microsurgery (TOLMS) or radiation therapy (RT), both providing comparable oncological outcomes but differing in functional results. Local recurrence occurs in approximately 10% of cases, making salvage surgery a crucial therapeutic option. This multi-institutional study investigates the efficacy of open partial horizontal laryngectomy (OPHL) as a salvage treatment, following recurrent laryngeal squamous-cell carcinoma (LSCC) after failed TOLMS. This analysis includes 66 patients who underwent OPHL between 1995 and 2017, reporting favorable oncological outcomes with overall survival (OS) of 87.4%, disease-specific survival (DSS) of 93.4%, and disease-free survival (DFS) of 85.5%. A recurrence rate of 10.6% was observed post-salvage OPHL, with vascular invasion and advanced pathological staging identified as significant predictors of recurrence. OPHL emerged as an effective organ-preserving alternative to total laryngectomy (TL) in select patients, especially those with limited tumor spread and preserved laryngeal function. The study highlights the importance of careful patient selection and thorough preoperative assessment to improve outcomes, positioning OPHL as a key option in treating recurrent laryngeal cancer and offering oncological control while preserving laryngeal functions.
早期喉癌(T1-T2)通常采用保留器官的技术进行治疗,如经口激光显微手术(TOLMS)或放射治疗(RT),两者的肿瘤学结局相当,但功能结果有所不同。约10%的病例会出现局部复发,这使得挽救性手术成为关键的治疗选择。这项多机构研究调查了开放性部分水平喉切除术(OPHL)作为TOLMS失败后复发性喉鳞状细胞癌(LSCC)挽救性治疗的疗效。该分析纳入了1995年至2017年间接受OPHL的66例患者,报告显示其肿瘤学结局良好,总生存率(OS)为87.4%,疾病特异性生存率(DSS)为93.4%,无病生存率(DFS)为85.5%。挽救性OPHL术后观察到复发率为10.6%,血管侵犯和高级别病理分期被确定为复发的重要预测因素。在特定患者中,尤其是肿瘤扩散有限且喉功能保留的患者,OPHL成为全喉切除术(TL)有效的保留器官替代方案。该研究强调了仔细的患者选择和全面的术前评估对改善结局的重要性,将OPHL定位为治疗复发性喉癌的关键选择,并在保留喉功能的同时实现肿瘤学控制。